LeVerage LFS is intended for use in the lower cervical and upper thoracic spine (C3 to T3) in laminoplasty procedures. LeVerage LFS is used to hold the allograft material in place in order to prevent the allograft material from expulsion, or impinging the spinal cord. Leverage LFS implants are made from titanium alloy. This material was selected for its stability, corrosion resistance and strong mechanical properties. Long-term clinical experience of the use of this material has shown that an acceptable level of biological response can be expected, if the material is used in appropriate applications.
About Nuvasive
NuVasive, Inc. (NASDAQ: NUVA) based in San Diego, California, is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. NuVasive’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products. NuVasive® is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine.
The Company is the third largest medical device company in the $8.2 billion global spine market. NuVasive’s principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches.
With over 90 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus. http://www.nuvasive.com